崔昊，藥物化學(xué)博士，校聘副教授，碩士生導(dǎo)師

研究方向：小分子藥物的設(shè)計(jì)、合成及生物活性研究

電子郵箱：cuih1008@ahmu.edu.cn

主要科研項(xiàng)目：

參與多項(xiàng)國家自然基金項(xiàng)目及省級(jí)項(xiàng)目

安徽省高校自然科學(xué)研究項(xiàng)目，2022AH050654；2023.1-2024.12，主持

2022年引進(jìn)人才博士科研啟動(dòng)經(jīng)費(fèi)，0601113201

主要發(fā)表論文：

1.Hao Cui,Guodong Zhang, Liyuan Zhang, Shilong Sun, Kang Yang, Aixin Gen, Penfeng Wang, Hui Wang, Qing-Qing Zhou, Hongmei Li, Yadong Chen, Yuqin Yao, Tao Lu*, Lei Zhang*, Yong Zhu*.Discovery ofN-phenyl-5-propyl-1H-pyrazole-3-carboxamide, with selective inhibition and degradation of HDAC6 for the treatment of acute liver injury. Journal of Medicinal Chemistry. 2025,68(1): 531-554.

2.Guo-Dong Zhang, Li-Li Wang, Ling Zheng, Shi-Qi Wang, Rong-Quan Yang, Yu-Ting He, Jun-Wei Wang, Ming-Yu Zhao, Yi Ding, Mei Liu, Tian-Yu Yang, Bao-Ming Wu*,Hao Cui*, Lei Zhang*. A novel HDAC6 inhibitor attenuate APAP-induced liver injury by regulating MDH1-mediated oxidative stress. International Immunopharmacology. 2024, 131: 111861.

3.Hao Cui#, Qianqian Hong#, Ran Wei, Hongmei Li, Chunyang Wan, Xin Chen, Shuang Zhao, Haizhi Bu, Bingxu Zhang, Dexiao Yang, Tao Lu*, Yadong Chen*, Yong Zhu*. Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. European Journal of Medicinal Chemistry. 2022 5(229): 114049.

4.Hao Cui, Jingkun Huang, Yan Lei, Quanwei Chen, Zan Hu, Jiaqi Niu, Ran Wei, Kang Yang, Hongmei Li, Tao Lu*, Yong Zhu*, Yatian Huang*. Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer. European Journal of Medicinal Chemistry. 2022 5(229): 114082.

5.Hao Cui#, Zan Hu#, Kang Yang, Jingkun Huang, Yichao Wu, Quanwei Chen, Ran Wei, Penfeng Wang, Hui Wang, Tao Lu*, Yuqin Yao*, Yong Zhu*. Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer. European Journal of Medicinal Chemistry. 2022 10(238): 114568.